Abstract
Background and aim: Alkaptonuria (AKU) clinical manifestations resemble severe arthritis. The Suitability of Nitisinone in Alkaptonuria 1 (SONIA 1) study is a dose-finding trial for nitisinone treatment of AKU patients. We tested a panel of serum and urinary biomarkers reflecting extracellular matrix remodelling (ECMR) of cartilage, bone and connective tissue in SONIA 1 patients to identify non-invasive and diagnostic biomarkers of tissue turnover in AKU.
Methods: Fasted serum and urine were retrieved from 40 SONIA 1 patients and 44 healthy controls. Established biomarkers of bone remodelling (CTX-I, P1NP, OC), cartilage remodelling (CTX-II, C2M, AGNx1) and inflammation (CRPM) as well as exploratory biomarkers of ECMR (C6M, VCANM, MIM, TIM) were measured at baseline in serum and urine by means of enzyme-linked immunosorbent assays (ELISAs) or automated systems (Elecsys 2010).
Results: The levels of bone resorption (CTX-I) and cartilage degradation (C2M) were elevated in AKU patients as compared to controls (p > 0.0001 and p = 0.03, respectively). Also tissue inflammation (CRPM) was elevated in AKU patients (p = 0.01). In addition all four exploratory biomarkers of ECMR (C6M, VCANM, MIM, TIM) were elevated in AKU patients compared to healthy controls. CTX-II was the only biomarker to be reduced in AKU patients. TIM was the only marker that showed a higher concentration than the normal assay range in AKU patients.
Conclusions: We have identified new potential biomarkers for assessment of cartilage, bone and cardiovascular remodelling in AKU and demonstrated the robustness of the assays used to measure the biomarker concentration in biological fluids.
Competing interests: None declared
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Arends S, Spoorenberg A, Houtman PM, Leijsma MK, Bos R, Kallenberg CG, Groen H, Brouwer E, van der V (2012) The effect of three years of TNFalpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 14:R98
Barascuk N, Vassiliadis E, Zheng Q, Wang Y, Wang W, Larsen L, Rasmussen LM, Karsdal MA (2011) Levels of circulating MMCN-151, a degradation product of mimecan, reflect pathological extracellular matrix remodeling in apolipoprotein E knockout mice. Biomark Insights 6:97–106
Barascuk N, Genovese F, Larsen L, Byrjalsen I, Zheng Q, Sun S, Hosbond S, Poulsen TS, Diederichsen A, Jensen JM, Mickley H, Register TC, Rasmussen LM, Leeming DJ, Christiansen C, Karsdal MA (2013) A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease. Int J Clin Exp Med 6:174–184
Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, Leeming DJ, Dam EB, Zheng Q, Qvist P, Karsdal MA (2011) Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM–increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 44:423–429
Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA (2014) Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum 43:470–478
Curtis SL, Roberts NB, Ranganath LR (2014) Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria. Clin Biochem 47:640–647
Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C (2009a) Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 17:384–389
Dam EB, Loog M, Christiansen C, Byrjalsen I, Folkesson J, Nielsen M, Qazi AA, Pettersen PC, Garnero P, Karsdal MA (2009b) Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 11:R115
Dorleijn DM, Luijsterburg PA, Bay-Jensen AC, Siebuhr AS, Karsdal MA, Rozendaal RM, Bos PK, Bierma-Zeinstra SM (2014) Association between biochemical cartilage markers and clinical symptoms in patients with hip osteoarthritis: cohort study with 2-year follow-up. Osteoarthritis Cartilage 23:57–62
Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–867
Hashimoto J, Garnero P, van der HD, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N (2009) A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol 19:273–282
Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C (2008) Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol 8:12
Karsdal MA, Byrjalsen I, Bay-Jensen AC, Henriksen K, Riis BJ, Christiansen C (2010) Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis–the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 11:125
Kenny D, Ptacin MJ, Bamrah VS, Almagro U (1990) Cardiovascular ochronosis: a case report and review of the medical literature. Cardiology 77:477–483
Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA (2010) Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)–assessment of corresponding epitopes. Clin Biochem 43:1249–1256
Lok ZS, Goldstein J, Smith JA (2013) Alkaptonuria-associated aortic stenosis. J Card Surg 28:417–420
Millucci L, Ghezzi L, Paccagnini E, Giorgetti G, Viti C, Braconi D, Laschi M, Geminiani M, Soldani P, Lupetti P, Orlandini M, Benvenuti C, Perfetto F, Spreafico A, Bernardini G, Santucci A (2014a) Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient. Mediators Inflamm 2014:258471
Millucci L, Ghezzi L, Braconi D, Laschi M, Geminiani M, Amato L, Orlandini M, Benvenuti C, Bernardini G, Santucci A (2014b) Secondary amyloidosis in an alkaptonuric aortic valve. Int J Cardiol 172:e121–e123
Pedersen SJ, Sorensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Moller J, Hasselquist M, Mikkelsen D, Skjodt T, Lambert R, Hansen A, Ostergaard M (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann Rheum Dis 70:1375–1381
Preston AJ, Keenan CM, Sutherland H, Wilson PJ, Wlodarski B, Taylor AM, Williams DP, Ranganath LR, Gallagher JA, Jarvis JC (2014) Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis 73:284–289
Ranganath LR, Jarvis JC, Gallagher JA (2013) Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol 66:367–373
Ranganath LR, Milan AM, Huges AT (2014) Suitability of nitisinone in alkaptonuria 1 (SONIA 1): an international, multicenter, randomized, open-label, no-treatment controlled, parallel-group, dose–response study to investigate the effect of once daily nitisinone on 24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis 0:1–6
Rosenquist C, Qvist P, Bjarnason N, Christiansen C (1995) Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439–1445
Siebuhr AS, Wang J, Karsdal M, Bay-Jensen AC, Jin Y, Zheng Q (2012) Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis. J Transl Med 10:195
Siebuhr AS, Petersen KK, Rendt-Nielsen Z, Egsgaard LL, Eskehave T, Christiansen C, Simonsen O, Hoeck HC, Karsdal MA, Bay-Jensen AC (2014) Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. Osteoarthritis Cartilage 22:44–50
Skjot-Arkil H, Schett G, Zhang C, Larsen DV, Wang Y, Zheng Q, Larsen MR, Nawrocki A, Bay-Jensen AC, Henriksen K, Christiansen C, Alexandersen P, Leeming DJ, Karsdal MA (2012) Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol 30:371–379
Soder S, Hambach L, Lissner R, Kirchner T, Aigner T (2002) Ultrastructural localization of type VI collagen in normal adult and osteoarthritic human articular cartilage. Osteoarthritis Cartilage 10:464–470
Syversen SW, Goll GL, van der HD, Landewe R, Gaarder PI, Odegard S, Haavardsholm EA, Kvien TK (2009) Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 36:266–272
Taylor AM, Boyde A, Wilson PJ, Jarvis JC, Davidson JS, Hunt JA, Ranganath LR, Gallagher JA (2011) The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum 63:3887–3896
Taylor AM, Boyde A, Davidson JS, Jarvis JC, Ranganath LR, Gallagher JA (2012a) Identification of trabecular excrescences, novel microanatomical structures, present in bone in osteoarthropathies. Eur Cell Mater 23:300–308
Taylor AM, Preston AJ, Paulk NK, Sutherland H, Keenan CM, Wilson PJ, Wlodarski B, Grompe M, Ranganath LR, Gallagher JA, Jarvis JC (2012b) Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage 20:880–886
Vassiliadis E, Rasmussen LM, Byrjalsen I, Larsen DV, Chaturvedi R, Hosbond S, Saabye L, Diederichsen AC, Genovese F, Duffin KL, Zheng Q, Chen X, Leeming DJ, Christiansen C, Karsdal MA (2012) Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker. J Transl Med 10:140
Veidal SS, Karsdal MA, Vassiliadis E, Nawrocki A, Larsen MR, Nguyen QH, Hagglund P, Luo Y, Zheng Q, Vainer B, Leeming DJ (2011) MMP mediated degradation of type VI collagen is highly associated with liver fibrosis–identification and validation of a novel biochemical marker assay. PLoS One 6:e24753
Vosse D, Landewe R, Garnero P, van der HD, van der LS, Geusens P (2008) Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) 47:1219–1222
Wang B, Chen P, Jensen AC, Karsdal MA, Madsen SH, Sondergaard BC, Zheng Q, Qvist P (2009) Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. BMC Res Notes 2:259
Zatkova A (2011) An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis 34:1127–1136
Acknowledgements
This study was funded by the European Union Seventh Framework Programme (project 304985) and by the Danish Research Fund (“Den Danske Forskningsfond”).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Verena Peters
Synopsis
Robust assays for non-invasive assessment of extracellular matrix turnover biomarkers can be used to describe the cartilage, bone and cardiovascular remodelling in alkaptonuria patients.
Compliance with Ethics Guidelines
Conflict of Interests
Federica Genovese is a full-time employee at Nordic Bioscience.
Anne Sofie Siebuhr is a full-time employee at Nordic Bioscience.
Kishwar Musa is a full-time employee at Nordic Bioscience.
Morten Karsdal is a full-time employee and holds shares at Nordic Bioscience.
Anne-Christine Bay-Jensen is a full-time employee and holds shares at Nordic Bioscience.
James Gallagher, Anna Milan, Jozef Rovensky and Lakshminarayan Ranganath declare that they have no conflict of interest.
Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Details of the Contributions of Individual Authors
Federica Genovese, Anne-Christine Bay-Jensen, Morten Karsdal, Jozef Rovensky and Lakshminarayan Ranganath conceived and designed the study; Kishwar Musa and Anna Milan performed the analysis; Federica Genovese, Anna Milan, Anne Sofie Siebuhr and Anne-Christine Bay-Jensen interpreted the data; Federica Genovese, Anne Sofie Siebuhr, James Gallagher, Anna Milan and Anne-Christine Bay-Jensen drafted the manuscript; and Anne-Christine Bay-Jensen, James Gallagher and Morten Karsdal revised the manuscript critically for important intellectual content.
Electronic Supplementary Material
Rights and permissions
Copyright information
© 2015 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Genovese, F. et al. (2015). Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria. In: Zschocke, J., Baumgartner, M., Morava, E., Patterson, M., Rahman, S., Peters, V. (eds) JIMD Reports, Volume 24. JIMD Reports, vol 24. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2015_430
Download citation
DOI: https://doi.org/10.1007/8904_2015_430
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48226-1
Online ISBN: 978-3-662-48227-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)